HOME » Subsidiary » Board of Directors

    Board of Directors - Vyome Therapeutics Limited - A Wholly Owned Subsidiary of Vyome Therapeutics Inc


    Dr. Raghunath A. Mashelkar, Chairman

    Dr. Raghunath Anant Mashelkar was the Director-General of the Council of Scientific and Industrial Research for over eleven years, and also served as the President of Indian National Science Academy.

    He is only the third Indian engineer to have been elected as Fellow of Royal Society (FRS), London in the twentieth century. He was elected Foreign Associate of the US National Academy of Science in 2005, Foreign Fellow of US National Academy of Engineering in 2003 and Fellow of Royal Academy of Engineering, UK in 1996. Dr. Mashelkar has won over 50 awards and medals from several bodies for his outstanding contribution in the field of science and technology. He has been awarded honorary doctorates by 27 universities from across the world. He is the only scientist so far to have won the JRD Tata Corporate Leadership Award. In 2011, Dr. Mashelkar was named National Research Professor by the Government of India.

    Ranjana Kumar, Board Member

    A career banker with 40 years’ experience in domestic and international banking, Mrs. Ranjana Kumar has been chairman of Indian Bank, Canara Bank and National Bank for Agriculture and Rural Development (NABARD). Most recently, she served as India's Chief Vigilance Commissioner in the Central Vigilance Commission.

    Mrs. Kumar was instrumental in transforming the Indian Bank from a loss-making entity to a viable business and was named 'India's Turnaround Queen' by The Economist for this achievement. Prior to Indian Bank, she was chairman of Canara Bank, and also served as CEO of Bank of India's US operations from 1995-99.

    In 2002, Business Standard named Mrs. Kumar 'Banker of the Year', and in 2013, she received the Lifetime Achievement Award from Business World magazine.

    Venkateswarlu (Venkat) Nelabhotla, Board Member

    Venkat brings a very rich and global experience of more than 25 years, successfully leading organizations in the biotech and cosmeceutics businesses. He held top management roles in biotech and pharmaceutical companies like ShanthaBiotechnics (A Sanofi Company) and Aurobindo Pharma, roles in which he immensely contributed to the Companies’ all-round growth. He was instrumental in creating market focus and orchestrating vaccine portfolio strategy in Shantha Biotech, a biosimilar and vaccine company, which was eventually acquired by Sanofi for $800 million. He has been a part of significant revenue growth and value creation in Aurobindo Pharma in the global business segment of APIs and finished dosage form products in multiple therapy areas.

    He has held CEO and President roles in Emami and Cavinkare, cosmeceutical and consumer product companies in India with global operations, creating value and growing them significantly with an all-rounded approach. During his time at Emami (a publicly listed company) as CEO, the company's market cap increased from $ 300 million to $ 1.2 billion. During the early part of his career, he created some very successful cosmeceutical brands in Cavinkare, and built the organization with a 10x revenue increase in 6 years' time.

    He comes with core strengths in Strategy, Innovation, Technology, Commercialization, Organization building, Finance, M&A. Venkat has received his B.Tech in Mechanical Engineering and an MBA from Indian Institute of Management - Ahmedabad, India.

    Contact Information: nvenkat@vyometx.com

    Dr. Shiladitya Sengupta, Board Member

    Dr. Shiladitya Sengupta is an assistant professor of medicine at Harvard Medical School. He is also the Co-Founder of Invictus Oncology, Cerulean Pharmaceuticals and Mitra Biotech. Shiladitya's research focuses on the development of novel nanomedicines for cancer and angiogenesis-based diseases. In 2005, he was recognized as one of the top 35 innovators worldwide by MIT Technology Review magazine. He has also received the Shakuntala Amir Chand Award from the Indian Council for Medical Research.

    Shiladitya is an alumnus of the All India Institute of Medical Sciences, and completed his PhD as a Nehru Scholar from Trinity College at Cambridge University and was a Fellow at MIT before joining Harvard. He has published over 35 papers, including in Nature and Proceedings of the National Academy of Sciences.

    Dr. Swaminathan Sivaram, Board Member

    Dr. Swaminathan Sivaram is a polymer chemist of high distinction. Dr. Sivaram is presently an INSA Senior Scientist and Honorary Professor at the Indian Institute of Science Education and Research, Pune, India. Prior to this he held the position of CSIR Bhatnagar Fellow (2010-15) and J.C. Bose National Fellow of the Department of Science and Technology (2007-15) at CSIR-NCL. Prior to this he served as the eighth Director of National Chemical Laboratory (NCL), one of the largest publicly funded research and development laboratories devoted to chemical sciences, from 2002-10. As Director of NCL, Dr. Sivaram built several public/private partnerships with industry, leading to process and product development, intellectual property licensing and technology transfer.

    An alumnus of IIT-Kanpur, he received his PhD in Chemistry from Purdue University. He was a Research Associate at the Institute of Polymer Science, University of Akron before returning to India to pursue his professional career. Dr. Sivaram has over 45 years of experience in basic research, process and product R&D and technology management, both in industry and academia. Dr. Sivaram is an elected Fellow of the Indian National Science Academy, Indian Academy of Sciences, National Academy of Sciences, and Indian National Academy of Engineering, New Delhi. He is also a Fellow of the International Union of Pure and Applied Chemistry (IUPAC). Dr. Sivaram is a highly decorated scientist with numerous awards to his credits The President of India recognized him with the award of Padma Sri in 2006. Purdue University conferred on him the DSc degree in 2010 for his exceptional attainment and merit.

    Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.